Product

Company

Clareo Health | HRD and Resistance to PAPPi in EOC Patients

NCT05310370·1 site·ClinicalTrials.gov

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Lei Li

Age

18–any

Sex

FEMALE

Healthy volunteers

Not accepted

Aged 18 years or older
Pathological confirmation of epithelial ovarian cancer
With available tumor tissues
Given consents to participate the study
With detailed follow-up outcomes
Declining to accept PARPi as maintenance therapy after the major treatment for cancer

The record

StatusUnknown

PhaseNo phase

Taking part400

StartedMar 2022

UpdatedApr 4, 2022

Conditions

Where1